IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026 - 20:22

IN8bio, a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, announced its financial results for the first quarter of 2026 along with key business updates. The company is advancing its next-generation gamma-delta T cell engager platform and expects to release initial animal data later this year.

In its glioblastoma program, IN8bio reported data showing a roughly 97 percent improvement in progression-free survival compared to standard-of-care treatment. The company plans to present updated median overall survival data at the ASCO 2026 conference.

IN8bio will host an R&D Day on May 21, 2026 in New York City to discuss its pipeline and future directions. The company continues to develop innovative gamma-delta T cell therapies designed to target and destroy cancer cells while potentially reducing side effects associated with traditional treatments.

Financial details from the first quarter were not disclosed in the summary, but the company remains focused on advancing its clinical programs and platform technology. IN8bio is headquartered in New York and trades on the Nasdaq under the ticker INAB.